JP MORGAN/CALL/BECTON DICKINSON AND CO./265/0.1/21.06.24 Share Price

Warrant

DE000JB03XZ7

Real-time Bid/Ask 07:16:41 03/06/2024 pm IST
0.093 EUR / 0.14 EUR +588.24% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./265/0.1/21.06.24
1 month-91.05%
3 months-97.64%
Date Price Change
03/24/03 0.05 +194.12%
31/24/31 0.017 +325.00%
30/24/30 0.004 +100.00%
29/24/29 0.002 -71.43%
28/24/28 0.007 0.00%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 12:09 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JB03XZ
ISINDE000JB03XZ7
Date issued 22/08/2023
Strike 265 $
Maturity 21/06/2024 (18 Days)
Parity 10 : 1
Emission price 3
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.54
Lowest since issue 0.002
Spread 0.155
Spread %67.39%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
232 USD
Average target price
278.7 USD
Spread / Average Target
+20.14%
Consensus